Alkermes Plc. (ALKS) Files Form 4 Insider Selling : Paul J Mitchell Sells 2,000 Shares

Alkermes Plc. (ALKS): Paul J Mitchell , director of Alkermes Plc. sold 2,000 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $44.97 per share for a total value of $89,950.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, Paul J Mitchell (director) sold 2,000 shares at $38.60 per share price.On Apr 20, 2016, Richard F Pops (Director and CEO, Alkermes plc) sold 18,750 shares at $40.15 per share price.Also, On Apr 20, 2016, Michael J Landine (SVP, Corp Dev., Alkermes, Inc.) sold 16,875 shares at $41.12 per share price.On Apr 20, 2016, Iain Michael Brown (VP Finance & CAO, Alkermes Inc) sold 5,368 shares at $39.27 per share price.

Shares of Alkermes Plc (ALKS) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -1.94 points or -4.13% at $45.06 with 11,72,741 shares getting traded. Post opening the session at $46.49, the shares hit an intraday low of $44.53 and an intraday high of $46.49 and the price vacillated in this range throughout the day. The company has a market cap of $6,812 M and the number of outstanding shares has been calculated to be 15,11,65,400 shares. The 52-week high of Alkermes Plc is $80.71 and the 52-week low is $27.14.

Alkermes Plc Money Flow Index Chart

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching developing and commercializing both with partners and on its own pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders such as addiction schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil ALKS 5461 ALKS 3831 ALKS 8700 and RDB 1419. The Company’s main marketed products include RISPERDAL CONSTA INVEGA SUSTENNA/XEPLION AMPYRA/FAMPYRA BYDUREON and VIVITROL.

Leave a Reply

Alkermes Plc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alkermes Plc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.